United States G-Protein Coupled Receptor (GPCR) Market Size & Outlook, 2026-2034
United States G-Protein Coupled Receptor (GPCR) Market Insights
- According to Deep Market Insights analysis, the United States G-Protein Coupled Receptor (GPCR) Market size was USD 906.59 Million in 2025 and is projected to reach USD 1734.19 Million by 2034.
- The United States market is projected to grow at a CAGR of 7.54% between 2026 and 2034.
- By segment, GPCR Cell Lines emerged as the largest By Product Type in terms of market size in 2025.
- Detection & Assay Kits is anticipated to remain the most attractive By Product Type segment, recording the fastest growth during the forecast period.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- United States accounted for 22.61% of the global G-Protein Coupled Receptor (GPCR) Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within North America, United States is forecasted to dominate the regional G-Protein Coupled Receptor (GPCR) Market size by 2034.
- United States will be the fastest-growing market in North America, projected to achieve USD 1744 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 906.59 Million |
| Market Size In 2034 | USD 1734.19 Million |
| Largest segment | GPCR Cell Lines |
| Units | Revenue in USD Million |
| CAGR | 7.54% (2026-2034) |
| Segmnetation Covered | |
| By Product Type |
|
| By Application |
|
| By End-User |
|
| By Technology Platform |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States G-Protein Coupled Receptor (GPCR) Market By Product Type 2026-2034 (USD Million)
| By Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GPCR Cell Lines | XX.x | XX.x | XX.x | 334.26 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Detection & Assay Kits | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cell Culture Reagents | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ligands (Agonists, Antagonists, Modulators) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| GPCR Libraries & Screening Panels | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States G-Protein Coupled Receptor (GPCR) Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Discovery & Target Identification | XX.x | XX.x | XX.x | 303.26 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Central Nervous System Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oncology Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cardiovascular Disease Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Metabolic Disorder Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Inflammation & Immunology Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Respiratory Disease Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States G-Protein Coupled Receptor (GPCR) Market By End-User 2026-2034 (USD Million)
| By End-User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Companies | XX.x | XX.x | XX.x | 339.16 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biotechnology Companies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Contract Research Organizations (CROs) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic & Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Government Research Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
United States G-Protein Coupled Receptor (GPCR) Market By Technology Platform 2026-2034 (USD Million)
| By Technology Platform | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell-Based GPCR Assays | XX.x | XX.x | XX.x | 359.74 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Label-Free Assays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reporter Gene Assays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fluorescence-Based Assays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Luminescence-Based Assays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biosensor-Based Assays | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.